Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 24-Sep-24 5:26 PM View:  | Klencke Barbara Director | Tscan Therapeutics, Inc. (TCRX) | 23-Sep-24 | Private Purchase | 5,000 | $5.29 | $26,450.00 | 8% 65.0K to 70.0K | |
| 27-Aug-24 6:57 PM View: | Klencke Barbara Director | Tscan Therapeutics, Inc. (TCRX) | 26-Aug-24 | Purchase | 5,000 | $5.53 | $27,650.00 | 8% 60.0K to 65.0K | |
| 27-Aug-24 6:46 PM View: | Zdraveski Zoran See Remarks | Tscan Therapeutics, Inc. (TCRX) | 23-Aug-24 | Option Sale | 157,186 | $5.78 | $908,755.00 | (93%) 169.4K to 12.22K | |
| 27-Aug-24 6:46 PM View: | Zdraveski Zoran See Remarks | Tscan Therapeutics, Inc. (TCRX) | 23-Aug-24 | Option Exercise | 157,186 | $3.38 | $531,520.00 | 1287% 12.22K to 169.4K | |
| 27-Aug-24 6:46 PM View: | Zdraveski Zoran See Remarks | Tscan Therapeutics, Inc. (TCRX) | 23-Aug-24 | Sale | 7,500 | $5.78 | $43,360.50 | (61%) 12.22K to 4.72K | |
| 27-Aug-24 6:57 PM View: | Klencke Barbara Director | Tscan Therapeutics, Inc. (TCRX) | 23-Aug-24 | Private Purchase | 5,000 | $5.69 | $28,450.00 | 9% 55.0K to 60.0K | |
| 21-Dec-23 5:00 PM View: | Barberich Timothy J Director | Tscan Therapeutics, Inc. (TCRX) | 19-Dec-23 | Purchase | 317 | $4.97 | $1,575.01 | < 1% 99.97K to 100.29K | |
| 21-Dec-23 5:00 PM View: | Barberich Timothy J Director | Tscan Therapeutics, Inc. (TCRX) | 18-Dec-23 | Private Purchase | 28,830 | $4.89 | $140,881.00 | 41% 71.14K to 99.97K | |
| 18-Dec-23 6:01 PM View: | Klencke Barbara Director | Tscan Therapeutics, Inc. (TCRX) | 14-Dec-23 | Private Purchase | 5,000 | $5.08 | $25,400.00 | 10% 50.0K to 55.0K | |
| 06-Jun-23 10:00 PM View: | Barberich Timothy J Director | Tscan Therapeutics, Inc. (TCRX) | 02-Jun-23 | Private Purchase | 37,880 | $2.63 | $99,563.80 | 114% 33.26K to 71.14K | |
| 02-Jun-23 5:35 PM View: | Lynx1 Capital Management Lp 10% Owner | Tscan Therapeutics, Inc. (TCRX) | 31-May-23 | Sale | 25,400 | $2.52 | $63,952.50 | (< 1%) 10.49M to 10.46M | |
| 29-Dec-22 2:34 PM View: | Silver Brian M. Chief Financial Officer | Tscan Therapeutics, Inc. (TCRX) | 28-Dec-22 | Purchase | 3,158 | $1.56 | $4,941.01 | 11% 29.73K to 32.88K | |
| 29-Dec-22 2:34 PM View: | Silver Brian M. Chief Financial Officer | Tscan Therapeutics, Inc. (TCRX) | 27-Dec-22 | Private Purchase | 2,842 | $1.50 | $4,276.36 | 11% 26.89K to 29.73K | |
| 20-May-22 4:15 PM View: | Southwell David P Chief Executive Officer Director | Tscan Therapeutics, Inc. (TCRX) | 18-May-22 | Private Purchase | 25,000 | $3.59 | $89,821.00 | 17% 146.57K to 171.57K | |
| 12-May-22 4:41 PM View: | Baker Bros Advisors LLC Director 10% Owner | Tscan Therapeutics, Inc. (TCRX) | 11-May-22 | Purchase | 25,865 | $1.99 | $51,349.80 | < 1% 2.76M to 2.78M | |
| 12-May-22 4:41 PM View: | Baker Bros Advisors LLC Director 10% Owner | Tscan Therapeutics, Inc. (TCRX) | 10-May-22 | Private Purchase | 1,333,930 | $1.88 | $2,507,800.00 | 94% 1.43M to 2.76M | |
| 28-Mar-22 4:31 PM View: | Silver Brian M. Chief Financial Officer | Tscan Therapeutics, Inc. (TCRX) | 24-Mar-22 | Private Purchase | 15,000 | $3.40 | $50,982.00 | 126% 11.88K to 26.89K | |
| 27-Dec-21 4:30 PM View: | Southwell David P Chief Executive Officer Director | Tscan Therapeutics, Inc. (TCRX) | 23-Dec-21 | Option Exercise | 48,670 | $1.97 | $95,879.90 | 50% 97.9K to 146.57K | |
| 27-Sep-21 5:22 PM View: | Zdraveski Zoran Chief Legal Officer | Tscan Therapeutics, Inc. (TCRX) | 23-Sep-21 | Market Purchase | 4,716 | $7.48 | $35,255.40 | 100% 0 to 4.72K | 6% |
| 22-Sep-21 10:00 PM View: | MacBeath Gavin Chief Scientific Officer | Tscan Therapeutics, Inc. (TCRX) | 21-Sep-21 | Market Purchase | 57 | $6.19 | $352.72 | < 1% 49.71K to 49.77K | 28% |
| 22-Sep-21 10:00 PM View: | Silver Brian M. Chief Financial Officer | Tscan Therapeutics, Inc. (TCRX) | 21-Sep-21 | Market Purchase | 5,000 | $6.32 | $31,585.00 | 73% 6.88K to 11.88K | 25% |
| 22-Sep-21 10:00 PM View: | MacBeath Gavin Chief Scientific Officer | Tscan Therapeutics, Inc. (TCRX) | 20-Sep-21 | Market Purchase | 4,943 | $6.22 | $30,744.00 | 11% 44.77K to 49.71K | 27% |
| 13-Sep-21 4:37 PM View: | Silver Brian M. Chief Financial Officer | Tscan Therapeutics, Inc. (TCRX) | 09-Sep-21 | Market Purchase | 5,885 | $8.48 | $49,925.40 | 589% 1.0K to 6.88K | (3%) |
| 09-Sep-21 4:43 PM View: | Southwell David P Chief Executive Officer Director | Tscan Therapeutics, Inc. (TCRX) | 08-Sep-21 | Market Purchase | 11,000 | $8.73 | $96,066.30 | 13% 86.9K to 97.9K | (2%) |
| 31-Aug-21 5:56 PM View: | Desmarais William Chief Business Officer | Tscan Therapeutics, Inc. (TCRX) | 27-Aug-21 | Market Purchase | 2,500 | $9.08 | $22,708.00 | 100% 0 to 2.5K | (5%) |
| 22-Jul-21 7:43 AM View: | Barberich Timothy J Director | Tscan Therapeutics, Inc. (TCRX) | 20-Jul-21 | Conversion | 33,259 | -- | -- | 100% 0 to 33.26K | |
| 22-Jul-21 4:06 PM View: | Baker Bros Advisors LLC Director | Tscan Therapeutics, Inc. (TCRX) | 20-Jul-21 | Purchase | 1,425,000 | $15.00 | $21,375,000.00 | 100% 0 to 1.43M | |
| 22-Jul-21 4:46 PM View: | Westphal Christoph H 10% Owner | Tscan Therapeutics, Inc. (TCRX) | 20-Jul-21 | Conversion | 1,145,500 | -- | -- | 111% 1.04M to 2.18M | |
| 22-Jul-21 4:46 PM View: | Westphal Christoph H 10% Owner | Tscan Therapeutics, Inc. (TCRX) | 20-Jul-21 | Purchase | 133,333 | $15.00 | $2,000,000.00 | 6% 2.18M to 2.32M | |
| 22-Jul-21 7:37 AM View: | Silver Brian M. Chief Financial Officer | Tscan Therapeutics, Inc. (TCRX) | 20-Jul-21 | Purchase | 1,000 | $15.00 | $15,000.00 | 100% 0 to 1.0K |
